Displaying 1–13 of 13 results for Girish Malhotra, President, EPCOT International

Sort By Relevance Sort By Date

Keeping Innovation in Our Hands

(Article)

FINAL DOSE: How to spur technological advancements in pharma.

Pharmaceutical Manufacturing Announces Updated Editorial Advisory Board

(News)

Pharmaceutical Manufacturing is honored to welcome three new editorial advisory board members, as we continue our ongoing quest to keep our brand current and unique.

The Good, the Bad & the Donald: CPhI Worldwide's 2017 Pharma Predictions

(Article)

CPhI Worldwide's 2017 Pharma Predictions: The Good, the Bad, and the Donald. Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities.

Financial Justification in Pharma

(Article)

Selection of any pharma manufacturing process, including supply chain and quality assurance practices, requires financial justification

State of the Union: Overview

(Article)

Pharmaceutical manufacturing capacity is increasingly global and going biologic, but challenged to meet the realities of cGMP

Will Chemical Engineers Save Pharma?

(Blog)

As Ranbaxy’s World Turns, So Does Generics Model

(Article)

Never a dull moment these days at Ranbaxy Laboratories, India’s largest drug manufacturer. In the course of the summer, it has resolved its longstanding, much-publicized patent dispute with Pfizer over its generic version of Lipitor, agreed to an imminent buyout by Japanese drugmaker Daiichi ...

Pharmaceutical Manufacturing: Is It the Antithesis of Creative Destruction?

(Article)

PAT and QbD can only move forward if the industry sheds its habit of QbA (i.e., quality by analysis)

Is IT a Catalyst for India’s Drug Industry Growth?

(Article)

API process development expert Girish Malhotra explores this question and its relevance to both Indian innovation and global competition in pharmaceuticals.

Big Pharma: Who's Your Role Model, Toyota or Edsel?

(Article)

Generic drug manufacturers must grapple with the tightest of all pharmaceutical profit margins. This is especially true of generic manufacturers in developing countries. Branded drug makers had not suffered from such constraints in the past, but this situation is about to change.

Less is More in API Process Development

(Article)

API manufacturers in India and China have grasped the need for simplicity, while U.S. process chemists continue along their costly and complex path. Girish Malhotra shares recommendations for improved API process development.

Sort By Relevance Sort By Date